The PPIL1 (Peptidyl-Prolyl Isomerase-Like 1) antibody is a research tool designed to detect and study the PPIL1 protein, a member of the cyclophilin family. PPIL1. also known as cyclophilin 60. functions as a peptidyl-prolyl cis-trans isomerase (PPIase), facilitating protein folding by catalyzing the isomerization of proline residues. It plays roles in diverse cellular processes, including RNA splicing, transcriptional regulation, and possibly cell cycle control. PPIL1 interacts with components of the spliceosome, such as SKIP and CDC5L, suggesting its involvement in pre-mRNA processing. Antibodies targeting PPIL1 are widely used in techniques like Western blotting, immunoprecipitation, and immunofluorescence to investigate its expression, localization, and molecular interactions. Research has linked PPIL1 to diseases such as cancer and neurodegenerative disorders, where altered expression or dysfunction may contribute to pathogenesis. For example, PPIL1 overexpression has been observed in certain tumors, implicating its potential as a biomarker or therapeutic target. These antibodies enable the exploration of PPIL1's regulatory mechanisms and its role in cellular homeostasis, providing insights into disease mechanisms and therapeutic strategies. Validation of PPIL1 antibodies for specificity and cross-reactivity is critical to ensure reliable experimental outcomes.